Nasdaq16 天
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP ...
pharmaphorum6 年
Pfizer's Talzenna PARP breast cancer drug approved in US
Talzenna is a poly (ADP-ribose) polymerase (PARP) inhibitor, and is the second drug of this class approved in breast cancer, after AstraZeneca's Lynparza (olaparib) earlier this year.